BioGend Therapeutics Co., Ltd.
BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd. (6733) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.013x
Based on the latest financial reports, BioGend Therapeutics Co., Ltd. (6733) has a cash flow conversion efficiency ratio of -0.013x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-9.75 Million) by net assets (NT$757.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioGend Therapeutics Co., Ltd. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how BioGend Therapeutics Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioGend Therapeutics Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioGend Therapeutics Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Miciso Real Estate SOCIMI S.A.
MC:YMCS
|
N/A |
|
DRAIG RESOURCES
BE:C7H
|
N/A |
|
KST BETEILIG N (KSW.SG)
STU:KSW
|
N/A |
|
Jr Global Reit
KO:348950
|
N/A |
|
Grounded People Apparel Inc.
PINK:GPAIF
|
-0.024x |
|
Robert Walters
LSE:RWA
|
0.020x |
|
Q2M Managementberatung AG
HM:QBI
|
N/A |
|
Visicons Construction and Investment JSC
VN:VC6
|
N/A |
Annual Cash Flow Conversion Efficiency for BioGend Therapeutics Co., Ltd. (2021–2025)
The table below shows the annual cash flow conversion efficiency of BioGend Therapeutics Co., Ltd. from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$757.64 Million | NT$-63.66 Million | -0.084x | +28.09% |
| 2024-12-31 | NT$846.51 Million | NT$-98.91 Million | -0.117x | +19.41% |
| 2023-12-31 | NT$956.77 Million | NT$-138.72 Million | -0.145x | +37.18% |
| 2022-12-31 | NT$731.27 Million | NT$-168.78 Million | -0.231x | -59.18% |
| 2021-12-31 | NT$943.45 Million | NT$-136.80 Million | -0.145x | -- |